Abstract 4369595: Long-Term Outcomes of Mechanical Versus Bioprosthetic Surgical Aortic Valve Replacement in Adults ≤55 Years: A Multicenter Analysis

I Issam Motairek (Cleveland Clinic Foundation, Cleveland, Ohio, United States) O Oussama Wazni (Cleveland Clinic, Cleveland, Ohio, United States) C Christine Jellis (Cleveland Clinic, Cleveland Heights, Ohio, United States) P Patrick Vargo (Cleveland Clinic, Cleveland, Ohio, United States) V Venu Menon (Cleveland Clinic Coordinating Center for Clinical Research (C5 Research), Cleveland Clinic, Cleveland) S Samir Kapadia W Wael Jaber (Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland)

Abstract

Background: Surgical aortic valve replacement (SAVR) in younger patients (<55 years) poses a clinical dilemma between mechanical and bioprosthetic valves. Long-term outcome comparisons remain limited in this age group. Methods: We analyzed a multicenter database of adults ≤55 who underwent SAVR with either a bioprosthetic or mechanical valve (n=6,306 in each group), excluding those with prior endocarditis. Propensity score matching balanced demographics and comorbidities. We examined 15-year outcomes including all-cause mortality, stroke, major bleeding, valve dysfunction, endocarditis, anticoagulant complications, new-onset atrial fibrillation/flutter, device implantation, and redo-intervention. Results: The mean age was 42.2 ± 14.0 years (bioprosthetic) and 42.1 ± 11.9 years (mechanical), and 30.6% vs. 31.3% were female (p=0.375), respectively. Long-term all-cause mortality was similar between groups (8.1% bioprosthetic vs. 8.3% mechanical; HR 1.00, 95% CI 0.89–1.13; p=0.73). Compared with mechanical valves, bioprosthetic valves were associated with lower risks of major bleeding (2.8% vs. 4.8%; HR 0.57, 95% CI 0.47–0.69; p<0.001) and anticoagulant complications (1.1% vs. 3.5%; HR 0.31, 95% CI 0.24–0.41; p<0.001). However, bioprosthetic valves had higher rates of valve dysfunction (6.1% vs. 3.3%; HR 2.00, 95% CI 1.70–2.35; p<0.001) and redo-SAVR (3.5% vs. 2.7%; HR 1.32, 95% CI 1.07–1.62; p=0.008). Bioprosthetic valves were also associated with lower risks of stroke (6.0% vs. 7.7%; HR 0.78, 95% CI 0.68–0.90; p<0.001), endocarditis (20.3% vs. 25.5%; HR 0.75, 95% CI 0.70–0.81; p<0.001), new-onset atrial fibrillation/flutter (11.4% vs. 13.5%; HR 0.85, 95% CI 0.76–0.94; p=0.002), and device implantation (7.4% vs. 8.5%; HR 0.88, 95% CI 0.78–0.99; p=0.035). Conclusion: In patients ≤55 undergoing SAVR, mortality was similar across valve types. Bioprosthetic valves were linked to fewer bleeding and anticoagulation-related complications, while mechanical valves carried higher risks of stroke, endocarditis, atrial fibrillation, and device implantation. These findings highlight the importance of individualized valve selection in younger adults.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (7)

I

Issam Motairek

Cleveland Clinic Foundation, Cleveland, Ohio, United States

O

Oussama Wazni

Cleveland Clinic, Cleveland, Ohio, United States

C

Christine Jellis

Cleveland Clinic, Cleveland Heights, Ohio, United States

P

Patrick Vargo

Cleveland Clinic, Cleveland, Ohio, United States

V

Venu Menon

Cleveland Clinic Coordinating Center for Clinical Research (C5 Research), Cleveland Clinic, Cleveland

S

Samir Kapadia

W

Wael Jaber

Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland